Literature DB >> 20956980

Molecular mechanisms of metastasis in breast cancer--clinical applications.

Michal Mego1, Sendurai A Mani, Massimo Cristofanilli.   

Abstract

The metastatic cascade is a series of biological processes that enable the movement of tumor cells from the primary site to a distant location and the establishment of a new cancer growth. Circulating tumor cells (CTCs) have a crucial role in tumor dissemination. The role of CTCs in treatment failure and disease progression can be explained by their relation to biological processes, including the epithelial-to-mesenchymal transition and 'self seeding', defined as reinfiltration of the primary tumor or established metastasis by more aggressive CTCs. CTCs are a unique and heterogeneous cell population with established prognostic and predictive value in certain clinical situations. The possibility of collecting sequential blood samples for real-time monitoring of systemic-therapy efficacy presents new possibilities to evaluate targeted therapies based on the genomic profiling of CTCs and to improve the clinical management of patients by personalized therapy. Interruption of the metastatic cascade via the targeting of CTCs might be a promising therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956980     DOI: 10.1038/nrclinonc.2010.171

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  96 in total

1.  Elevated tissue factor procoagulant activity in CD133-positive cancer cells.

Authors:  C Milsom; G M Anderson; J I Weitz; J Rak
Journal:  J Thromb Haemost       Date:  2007-09-19       Impact factor: 5.824

Review 2.  An overview of epithelio-mesenchymal transformation.

Authors:  E D Hay
Journal:  Acta Anat (Basel)       Date:  1995

Review 3.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

4.  Systemic spread is an early step in breast cancer.

Authors:  Yves Hüsemann; Jochen B Geigl; Falk Schubert; Piero Musiani; Manfred Meyer; Elke Burghart; Guido Forni; Roland Eils; Tanja Fehm; Gert Riethmüller; Christoph A Klein
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

5.  A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells.

Authors:  Mark M Fuster; Jillian R Brown; Lianchun Wang; Jeffrey D Esko
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 6.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

7.  Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1.

Authors:  Ichiro Ota; Xiao-Yan Li; Yuexian Hu; Stephen J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

8.  Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.

Authors:  I Van der Auwera; D Peeters; I H Benoy; H J Elst; S J Van Laere; A Prové; H Maes; P Huget; P van Dam; P B Vermeulen; L Y Dirix
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

Authors:  Tanja Fehm; Sven Becker; Silke Duerr-Stoerzer; Karl Sotlar; Volkmar Mueller; Diethelm Wallwiener; Nancy Lane; Erich Solomayer; Jonathan Uhr
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  78 in total

1.  Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.

Authors:  Sébastien Tabariès; Fanny Dupuy; Zhifeng Dong; Anie Monast; Matthew G Annis; Jonathan Spicer; Lorenzo E Ferri; Atilla Omeroglu; Mark Basik; Eitan Amir; Mark Clemons; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 2.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Authors:  Leticia De Mattos-Arruda; Javier Cortes; Libero Santarpia; Ana Vivancos; Josep Tabernero; Jorge S Reis-Filho; Joan Seoane
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

3.  Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

Authors:  Antonio Giordano; Hui Gao; Simone Anfossi; Evan Cohen; Michal Mego; Bang-Ning Lee; Sanda Tin; Michele De Laurentiis; Charla A Parker; Ricardo H Alvarez; Vicente Valero; Naoto T Ueno; Sabino De Placido; Sendurai A Mani; Francisco J Esteva; Massimo Cristofanilli; James M Reuben
Journal:  Mol Cancer Ther       Date:  2012-09-12       Impact factor: 6.261

Review 4.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 5.  The Paradox of p53: What, How, and Why?

Authors:  Yael Aylon; Moshe Oren
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression.

Authors:  E-S Kim; S Y Kim; M Koh; H-M Lee; K Kim; J Jung; H S Kim; W K Moon; S Hwang; A Moon
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

7.  An automated high-throughput counting method for screening circulating tumor cells in peripheral blood.

Authors:  Mengxia Zhao; Perry G Schiro; Jason S Kuo; Karen M Koehler; Daniel E Sabath; Viorica Popov; Qinghua Feng; Daniel T Chiu
Journal:  Anal Chem       Date:  2013-02-06       Impact factor: 6.986

8.  Circulating giant macrophages as a potential biomarker of solid tumors.

Authors:  Daniel L Adams; Stuart S Martin; R Katherine Alpaugh; Monica Charpentier; Susan Tsai; Raymond C Bergan; Irene M Ogden; William Catalona; Saranya Chumsri; Cha-Mei Tang; Massimo Cristofanilli
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy.

Authors:  María José Serrano; Pedro Sánchez Rovira; I Martínez-Zubiaurre; Miguel Delgado Rodriguez; Mónica Fernández; Jose A Lorente
Journal:  Exp Ther Med       Date:  2012-04-05       Impact factor: 2.447

Review 10.  Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo.

Authors:  Jin-Woo Kim; Ekaterina I Galanzha; David A Zaharoff; Robert J Griffin; Vladimir P Zharov
Journal:  Mol Pharm       Date:  2013-02-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.